Difficult to control atopic dermatitis
Options
BORIS DOI
Date of Publication
2013
Publication Type
Article
Division/Institute
Contributor
Darsow, Ulf | |
Wollenberg, Andreas | |
Taïeb, Alain | |
Werfel, Thomas | |
Oranje, Arnold | |
Svensson, Ake | |
Deleuran, Mette | |
Gelmetti, Carlo | |
Calza, Anne-Marie | |
Giusti, Francesca | |
Lübbe, Jann | |
Seidenari, Stefania | |
Ring, Johannes | |
European Task Force on Atopic Dermatitis / EADV Eczema Task, the |
Subject(s)
Series
World Allergy Organization journal
ISSN or ISBN (if monograph)
1939-4551
Publisher
BioMed Central
Language
English
Publisher DOI
PubMed ID
23663504
Description
Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial / antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. "Eczema school" educational programs have been proven to be helpful.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| 1939-4551-6-6.pdf | text | Adobe PDF | 765.18 KB | published |